Welcome to the Instem Investor Centre

Globe

Instem (AIM:INS.L) is a leading provider of IT applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.

Instem’s Early Development Applications (EDA’s) are used in evaluation studies to:

  • collect, analyse and report complex scientific data;
  • comply with regulatory reporting requirements;
  • improve quality, consistency and efficiency of information reporting; and
  • reduce the time of critical path R&D activities.

Instem’s solutions are supplied to an international blue chip customer base including AstraZeneca, GlaxoSmithKline and Charles River Laboratories.

Share price



Instem chief has more acquisitions in the pipeline after Samarind deal

Instem Plc  ( LON:INS ) has bought Samarind, a specialist in regulatory information manage...

Instem makes £2.5mln, earnings enhancing swoop for Samarind

Samarind “aligns perfectly with our strategy of expanding organically and acquisitively into adjacen...

Instem PLC looking for new acquisitions after strong 2015, says CFO

Nigel Goldsmith, chief financial officer of Instem Plc ( LON:INS ) tells Proactive the firm ha...

Instem PLC revenues and profits grow "significantly"

Revenues increased by 22% in the 12 months to December 31 to £16.3mln, £10mln of which were recurrin...

New Research Note 'A Day to Remember' - Instem Analyst & Investor Day




Featured Video

Instem chief has more acquisitions in the pipeline after Samarind deal

Instem is a robust business, with net cash and a valuable customer base delivering high levels of recurring revenue. The business continues to increase its strong global market share and is well positioned to take advantage of the structural changes in the drug development industry. Both the regulatory and fiscal environments continue to be favourable to Instem, driving demand for all areas of our product suite.

We will continue to expand the Group's reach into complementary scientific domains as part of our growth strategy.

Phil Reason,
Chief Executive